Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements

Tenaya Therapeutics Inc. TNYA on Friday reported interim Phase 1b/2 RIDGE-1 data showing its TN-401 gene therapy reduced ...

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...

All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated ...